Who Makes Ozempic: The Company and Its GLP-1 Lineup

Welcome to the PlexusDx Education Hub, where we translate the fast-moving world of GLP-1 therapy, weight-management protocols, and metabolic genetics into plain, decision-ready guidance. Explore the full Peptides & GLP-1 library.

"Who makes Ozempic" has a one-word answer, but the more useful story is the portfolio and rivalry around it. Ozempic comes from Novo Nordisk, one of the two companies that dominate GLP-1 therapy as of April 2026. Here is how its lineup is organized, how it compares with its chief competitor, and what genetics adds beneath all of it.

Novo Nordisk’s GLP-1 portfolio at a glance

Novo Nordisk markets Ozempic (semaglutide, FDA-approved for type 2 diabetes in 2017), Wegovy (semaglutide 2.4 mg, approved for chronic weight management in 2021), and Rybelsus (oral semaglutide, approved for type 2 diabetes in 2019). It also markets two liraglutide products: Victoza (approved for type 2 diabetes in 2010, with a 2017 cardiovascular indication) and Saxenda (liraglutide 3 mg, approved for chronic weight management in 2014). Its pipeline includes emerging obesity agents such as CagriSema, a cagrilintide-plus-semaglutide combination.

Same molecule, different labels

Three of those products share one active ingredient, semaglutide, and differ by format and approved use. That is why Ozempic and Rybelsus carry diabetes indications while Wegovy carries a weight-management indication despite the shared chemistry. The pattern illustrates a broader truth about this category: the brand name signals the approved use, not the underlying molecule.

How Novo Nordisk lines up against Eli Lilly

The two dominant makers pursue distinct molecular strategies. Novo Nordisk concentrates on GLP-1-selective compounds such as semaglutide and liraglutide, while Eli Lilly markets the only FDA-approved GIP/GLP-1 dual agonist, tirzepatide, and also offers a GLP-1-selective option, dulaglutide. Head-to-head trials, including SURPASS-2 (tirzepatide versus semaglutide 1 mg in type 2 diabetes) and SUSTAIN 7 (semaglutide versus dulaglutide), inform the competitive picture, though direct weight-management head-to-head data remain limited.

Where costs sit across makers

Manufacturer list prices are broadly similar across branded products in this space, typically $800 to $1,600 per month at U.S. list as of April 2026. Savings-card programs differ by product, and patient-assistance programs exist at both companies for eligible uninsured or underinsured patients. Compounded alternatives through 503A pharmacies are priced separately from any branded list.

The safety profile they share

Every FDA-approved GLP-1 receptor agonist and GIP/GLP-1 dual agonist across both manufacturers carries the class boxed warning for thyroid C-cell tumor risk observed in rodent studies, and each is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Common side effects are gastrointestinal, and rare serious events include pancreatitis, gallbladder problems, and acute kidney injury in the setting of dehydration.

What PlexusDx offers here

PlexusDx does not sell branded Ozempic; it offers the active ingredients semaglutide and tirzepatide through its Weight Management Protocols, including Semaglutide Injection and Tirzepatide Injection, as compounded formulations with published pricing.

The genetic layer sitting underneath the pathway

Two people can follow an identical protocol and experience very different appetite shifts, energy, and tolerability. A meaningful part of that spread traces back to inherited biology. Variants in FTO influence hunger set-points and fat storage, MC4R helps govern the melanocortin appetite circuit, TCF7L2 is tied to glucose handling, and GLP1R shapes how the GLP-1 receptor itself behaves. The PlexusDx Precision Peptide Genetic Test maps 14 pathways, 49 peptides, 150+ genetic insights across this terrain, giving you and your clinician a portrait of the metabolic tendencies you started with. To be explicit: this is trait and pathway education, not a forecast of how you will respond to any drug or medication. It is the upstream context, the "test before you invest" step, that makes the conversation about any weight management protocol a more informed one.

Frequently Asked Questions

What company makes Ozempic?

Ozempic is made by Novo Nordisk, one of the two manufacturers that dominate the GLP-1 category. The company also produces Wegovy and Rybelsus, which share semaglutide as their active ingredient, along with the liraglutide products Victoza and Saxenda, each carrying its own FDA-approved indication and format.

Which maker produces the stronger GLP-1 option?

Effectiveness is trial-specific and population-specific rather than settled by brand. SURPASS-2 and SUSTAIN 7 inform the comparison, but direct weight-management head-to-head data are limited, and individual response varies. Rather than ranking makers, the practical answer is to discuss options and evidence with a qualified healthcare provider.

Are Novo Nordisk and Eli Lilly prices very different?

Not dramatically at list. Branded products in this class generally fall in the $800 to $1,600 per month range at U.S. list as of April 2026. What varies more is savings-program eligibility, insurance coverage, and the indication on your prescription, which shape out-of-pocket cost more than the manufacturer name does.

Does genetics tell me which maker’s product suits me?

No. The Precision Peptide Genetic Test does not predict response to any manufacturer’s product. It analyzes pathway-level variants such as FTO, GLP1R, MC4R, and TCF7L2 that shape baseline metabolic biology, offering upstream context that applies across both companies’ GLP-1 compounds rather than a brand recommendation.

Keep reading across the PlexusDx Education Hub for more evidence-based explainers on the GLP-1 pathway. Return to the education hub.